Macrolipasemia secondary to colon cancer chemotherapy: a case report.

capecitabine chemotherapy macrolipasemia oxaliplatin pancreatitis

Journal

Biochemia medica
ISSN: 1846-7482
Titre abrégé: Biochem Med (Zagreb)
Pays: Croatia
ID NLM: 9610305

Informations de publication

Date de publication:
15 Oct 2021
Historique:
received: 18 06 2021
accepted: 29 08 2021
entrez: 18 10 2021
pubmed: 19 10 2021
medline: 26 10 2021
Statut: ppublish

Résumé

We reported macrolipasemia in a colon cancer patient during the chemotherapy period without any evidence of pancreatitis. A 52-year-old man formerly treated for papillary thyroid carcinoma had elevated a carcinoembryonic antigen (CEA) concentration in the latest control and was diagnosed with colon cancer. Xelox chemotherapy (oxaliplatin and capecitabine) protocol was planned for six months. Interestingly, the lipase activities gradually increased from 30 U/L to 434 U/L, and exceeded three times the upper limit of the reference range (13-60 U/L). There were no symptoms of pancreatitis, and the abdominal computed tomography (CT) scan was also normal. Polyethylene glycol (PEG) recovery % values of serum samples gradually decreased and were 27% in the recent sample before the end of chemotherapy. Interestingly, the serum lipase activity fell a month after chemotherapy, and PEG recovery % increased (39%). We considered the following possibilities: (1) macrolipasemia due to chemotherapy drugs, (2) macrolipasemia due to antibodies against chemotherapy drugs.

Identifiants

pubmed: 34658648
doi: 10.11613/BM.2021.030801
pii: bm-31-3-030801
pmc: PMC8495620
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

030801

Informations de copyright

Croatian Society of Medical Biochemistry and Laboratory Medicine.

Déclaration de conflit d'intérêts

Potential conflict of interest None declared.

Références

Am J Gastroenterol. 1995 Dec;90(12):2233-4
pubmed: 8540526
Bratisl Lek Listy. 2004;105(7-8):260-3
pubmed: 15543847
Pancreas. 1998 Mar;16(2):205-10
pubmed: 9510145
Clin Pharmacokinet. 2000 Jan;38(1):1-21
pubmed: 10668856
Clin Pharmacokinet. 2001;40(2):85-104
pubmed: 11286326
Pharmacotherapy. 2003 Aug;23(8):1076-8
pubmed: 12921254
Acta Clin Belg. 2011 Jan-Feb;66(1):63-5
pubmed: 21485769
Clin Chem. 1996 Mar;42(3):462-4
pubmed: 8598114
Clin Chim Acta. 2011 May 12;412(11-12):1161-2
pubmed: 21062625
Clin Chem. 1994 Jun;40(6):939-42
pubmed: 7522137
Anticancer Res. 2010 Dec;30(12):5113-5
pubmed: 21187498
Clin J Gastroenterol. 2020 Aug;13(4):626-631
pubmed: 31916217
Am J Gastroenterol. 1999 Feb;94(2):463-9
pubmed: 10022647
Intern Med. 2000 Dec;39(12):1115-8
pubmed: 11197804
BMC Cancer. 2016 Feb 17;16:118
pubmed: 26887807
Clin Chem. 1989 Dec;35(12):2261-70
pubmed: 2686862

Auteurs

Hatice Saracoglu (H)

Department of Medical Biochemistry, Medical Faculty, Erciyes University, Kayseri, Turkey.

Gulden Baskol (G)

Department of Medical Biochemistry, Medical Faculty, Erciyes University, Kayseri, Turkey.

Mevlut Baskol (M)

Department of Gastroenterology, Medical Faculty, Erciyes University, Kayseri, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH